Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.32 |
| ▸ | LMNA | P02545 | 3/20 | 0.32 |
| ▸ | HPGD | P15428 | 2/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29418156 | 1.00 | ALDH1A1 (0.32) | ALDH1A1LMNAHPGDALOX15HSD17B10 | |
| SCHEMBL29314886 | 0.88 | — | — | |
| SCHEMBL862169 | 0.73 | — | — | |
| SCHEMBL6971167 | 0.71 | — | — | |
| SCHEMBL23718957 | 0.70 | KDM1A (0.34) | ALDH1A1LMNAHPGDALOX15HSD17B10 | |
| SCHEMBL10112216 | 0.69 | — | — | |
| SCHEMBL8196368 | 0.67 | — | — | |
| SCHEMBL10817076 | 0.67 | — | — | |
| SCHEMBL6889293 | 0.65 | — | — | |
| SCHEMBL17654515 | 0.65 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 189 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4688781-A1 | METHODS AND REAGENTS FOR SYNTHESIZING HALOALDEHYDES, AND USES THEREOF | Simon Fraser University (CA) | 2026-02-11 | — | — | EP | claimed |
| CN-119528788-A | Method for breaking C-N bond and prepared carboglucosides and cyclic ether compounds | 南开大学 | 2025-02-28 | — | — | CN | claimed |
| WO-2024201390-A1 | METHODS AND REAGENTS FOR SYNTHESIZING HALOALDEHYDES, AND USES THEREOF | SIMON FRASER UNIVERSITY (CA) | 2024-10-03 | — | — | WO | claimed |
| CN-117658856-A | Method for synthesizing high-purity losartan biphenyl | 多氟多新材料股份有限公司 | 2024-03-08 | — | — | CN | claimed |
| CN-114989130-B | Preparation method of vinylene carbonate | 多氟多新材料股份有限公司 | 2023-10-31 | — | — | CN | claimed |
| CN-116655512-A | Preparation process of captopril | 江苏阿尔法药业股份有限公司 | 2023-08-29 | — | — | CN | claimed |
| CN-114989130-A | Preparation method of vinylene carbonate | 多氟多新材料股份有限公司 | 2022-09-02 | — | — | CN | claimed |
| EP-3034512-B1 | A process for producing iron (III) casein N-acetyl-aspartylated complexes and use thereof in pharmaceutical compositions | TSETI IOULIA (GR) | 2017-12-06 | — | — | EP | claimed |
| US-20170340747-A1 | PROCESS FOR PRODUCING IRON (III) CASEIN N-ACETYL-ASPARTYLATED COMPLEXES AND USE THEREOF IN PHARMACEUTICAL COMPOSITIONS | TSETI IOULIA (GR) | 2017-11-30 | — | — | US | claimed |
| WO-2016096203-A1 | A PROCESS FOR PRODUCING IRON (III) CASEIN N-ACETYL-ASPARTYLATED COMPLEXES AND USE THEREOF IN PHARMACEUTICAL COMPOSITIONS | TSETI IOULIA (GR) | 2016-06-23 | — | — | WO | claimed |
| EP-3034512-A1 | A process for producing iron (III) casein N-acetyl-aspartylated complexes and use thereof in pharmaceutical compositions | Tseti, Ioulia (GR) | 2016-06-22 | — | — | EP | claimed |
| EP-4211119-B1 | 2-AMINOQUINAZOLINES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | MERCK SHARP & DOHME LLC (US) | 2026-05-13 | — | — | EP | disclosed |
| EP-4234030-B1 | PD-1/PD-L1 INHIBITORS | GILEAD SCIENCES INC (US) | 2026-04-08 | — | — | EP | disclosed |
| EP-4720053-A1 | LACTAM PESTICIDAL COMPOUNDS | BASF SE (DE) | 2026-04-08 | — | — | EP | disclosed |
| US-12590062-B2 | PD-1/PD-L1 inhibitors | GILEAD SCIENCES, INC. (US) | 2026-03-31 | — | — | US | disclosed |
| WO-2018041964-A1 | IMIDAZOLE DERIVATIVES AND THEIR USE IN THE TREATMENT OF AUTOIMMUNE OR INFLAMMATORY DISEASES OR CANCERS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2018-03-08 | — | — | WO | disclosed |
| US-20180022763-A1 | Anti-Viral Compounds | ABBVIE INC. (US) | 2018-01-25 | — | — | US | disclosed |
| US-9676797-B2 | Anti-viral compounds | ABBVIE INC. (US) | 2017-06-13 | — | — | US | disclosed |
| WO-2017074832-A1 | FACTOR XIa INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2017-05-04 | — | — | WO | disclosed |
| US-20170057981-A1 | Anti-Viral Compounds | ABBVIE INC. (US) | 2017-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170057981-A1 | Anti-Viral Compounds | HAVCR2, EIF2AK2, MAVS | ALDH1A1 1641/4885LMNA 3478/4885HPGD 3587/4885 |
| US-12590062-B2 | PD-1/PD-L1 inhibitors | CD274, PDCD1LG2, PDCD1 | ALDH1A1 409/4885LMNA 1139/4885HPGD 3944/4885 |
| US-20180022763-A1 | Anti-Viral Compounds | HAVCR2, EIF2AK2, MAVS | ALDH1A1 1641/4885LMNA 3478/4885HPGD 3587/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.